MiRagen Therapeutics Inc logo

MGEN - MiRagen Therapeutics Inc Share Price

$1.09 0.0  0.0%

Last Trade - 07/08/20

Sector
Healthcare
Size
Micro Cap
Market Cap £44.3m
Enterprise Value £22.3m
Revenue £3.77m
Position in Universe 4683rd / 6395
Bullish
Bearish
Unlock MGEN Revenue
Momentum
Relative Strength (%)
1m +1.57%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -52.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
4.32 2.54 3.48 4.00 8.39 4.46 2.04 6.64 +0.6%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Miragen Therapeutics Inc revenues increased from $372K to $828K. Net loss decreased 31% to $8M. Revenues reflect Collaboration revenue increase of 96% to $681K, Grant revenue increase from $24K to $147K. Lower net loss reflects Research and Development - Balancing val decrease of 31% to $5.7M (expense), Selling and marketing - Balancing value decrease of 18% to $2.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

MGEN Revenue Unlock MGEN Revenue

Net Income

MGEN Net Income Unlock MGEN Revenue

Normalised EPS

MGEN Normalised EPS Unlock MGEN Revenue

PE Ratio Range

MGEN PE Ratio Range Unlock MGEN Revenue

Dividend Yield Range

MGEN Dividend Yield Range Unlock MGEN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MGEN EPS Forecasts Unlock MGEN Revenue
Profile Summary

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is involved in discovering and developing a pipeline of pre-clinical product candidates. Its pre-clinical product candidates include MRG-107 and MRG-110.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated December 8, 2010
Public Since June 18, 2014
No. of Shareholders: 18
No. of Employees: 45
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 53,077,348
Free Float (0.0%)
Eligible for
ISAs
SIPPs
MGEN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for MGEN
Upcoming Events for MGEN
Frequently Asked Questions for miRagen Therapeutics Inc
What is the miRagen Therapeutics Inc share price?

As of 07/08/20, shares in miRagen Therapeutics Inc are trading at $1.09, giving the company a market capitalisation of £44.3m. This share price information is delayed by 15 minutes.

How has the miRagen Therapeutics Inc share price performed this year?

Shares in miRagen Therapeutics Inc are currently trading at $1.09 and the price has moved by -16.15% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the miRagen Therapeutics Inc price has moved by -26.93% over the past year.

What are the analyst and broker recommendations for miRagen Therapeutics Inc?

Of the analysts with advisory recommendations for miRagen Therapeutics Inc, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for miRagen Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will miRagen Therapeutics Inc next release its financial results?

miRagen Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the miRagen Therapeutics Inc dividend yield?

miRagen Therapeutics Inc does not currently pay a dividend.

Does miRagen Therapeutics Inc pay a dividend?

miRagen Therapeutics Inc does not currently pay a dividend.

When does miRagen Therapeutics Inc next pay dividends?

miRagen Therapeutics Inc does not currently pay a dividend.

How do I buy miRagen Therapeutics Inc shares?

To buy shares in miRagen Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of miRagen Therapeutics Inc?

Shares in miRagen Therapeutics Inc are currently trading at $1.09, giving the company a market capitalisation of £44.3m.

Where are miRagen Therapeutics Inc shares listed? Where are miRagen Therapeutics Inc shares listed?

Here are the trading details for miRagen Therapeutics Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: MGEN
What kind of share is miRagen Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, miRagen Therapeutics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a miRagen Therapeutics Inc share price forecast 2020?

Shares in miRagen Therapeutics Inc are currently priced at $1.09. At that level they are trading at 0.377% discount to the analyst consensus target price of 0.00.

Analysts covering miRagen Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.576 for the next financial year.

How can I tell whether the miRagen Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like miRagen Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 37.23%. At the current price of $1.09, shares in miRagen Therapeutics Inc are trading at 40.41% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the miRagen Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for miRagen Therapeutics Inc.

Who are the key directors of miRagen Therapeutics Inc?

miRagen Therapeutics Inc's management team is headed by:

William Marshall - PRE
Thomas Hughes - IND
Kevin Koch - IND
Joseph Turner - IND
Jason Leverone - CFO
Jeffrey Hatfield - CHM
Christopher Bowden - IND
Arlene Morris - IND
Diana Escolar - OTH
Lee Rauch - COO
Who are the major shareholders of miRagen Therapeutics Inc?

Here are the top five shareholders of miRagen Therapeutics Inc based on the size of their shareholding:

Fidelity Management & Research Company Investment Advisor
Percentage owned: 6.87% (3.89m shares)
Fidelity Select Biotechnology Portfolio Mutual Fund
Percentage owned: 6.87% (3.89m shares)
Atlas Venture Venture Capital
Percentage owned: 5.55% (3.14m shares)
Remeditex Ventures, L.L.C. Corporation
Percentage owned: 4.78% (2.71m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.85% (1.61m shares)
Similar to MGEN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.